Clinical Trials

Burkitt Lymphoma

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

30 enrolled

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT05091424 2026-03-03

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

137 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

28 enrolled

Burkitt Lymphoma, Recurrence

NCT05053659 2026-02-12

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

23 enrolled

Lymphoma, Non-Hodgkin

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

23 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04843904 2026-01-07

SAVE

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

69 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

22 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03713580 2025-07-01

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

25 enrolled

Lymphoma, Non-Hodgkin

NCT05618366 2025-04-08

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

38 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

272 enrolled

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

11 enrolled 16 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

78 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT03136497 2024-09-23

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

10 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

LymphoidOther hematologic neoplasmPlasma cell

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT03557619 2024-08-29

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

12 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Hematologic Neoplasms

NCT04790903 2024-07-11

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

24 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

LymphoidMyeloidOther hematologic neoplasm

21 enrolled

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03739554 2024-01-25

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

5 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03884972 2023-09-25

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

Phase 1 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05005299 2023-08-01

VICTORY

LymphoidMyeloidOther hematologic neoplasmPlasma cell

18 enrolled

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01682616 2023-06-06

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

49 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03236857 2023-05-22

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

CNSLymphoidOther hematologic neoplasm

143 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Neuroblastoma, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03357627 2023-02-08

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

43 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03082209 2022-12-09

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

GastrointestinalLymphoidOther hematologic neoplasm

153 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT03036904 2022-08-24

V+DA-EPOCH-R

31 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02877550 2022-06-10

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

25 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT02419560 2022-05-24

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

37 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT01328626 2022-02-23

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

222 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03255096 2022-01-24

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

39 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03797261 2021-12-07

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

9 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT03181126 2021-10-14

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

69 enrolled

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01742988 2021-05-06

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

106 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01671904 2020-10-14

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

84 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01685892 2020-01-10

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

82 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01969695 2019-12-19

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

11 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence

NCT02391480 2019-11-29

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer